HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Francesco Sclafani
No relevant relationships to disclose
Amitesh Chandra Roy
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Merck Serono (U); Roche
Honoraria - Roche; Sanofi
Research Funding - Merck; Roche
Andrew Wotherspoon
No relevant relationships to disclose
Clare Peckitt
No relevant relationships to disclose
Alice Dewdney
No relevant relationships to disclose
Jacqueline Rose Oates
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Merck; Roche; Roche (U); Sanofi
Honoraria - Merck; Roche; Sanofi
Research Funding - Merck KGaA; Roche